Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUM-D
NCT05017311Phase 4Recruiting
- Sponsor
- Nova Scotia Health
- Start
- Jan 2023
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of brexpiprazole orally disintegrating tablet in major depressive disorder (MDD) (4 arms), sponsored by Nova Scotia Health. Primary endpoint: Montgomery Asberg Depression Rating Scale at 8 weeks. Started Jan 2023; status: recruiting.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05017311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05017311.